Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas. Show more

3060 Pegasus Park Drive, Dallas, TX, 75247, United States

Biotechnology

Healthcare

Market Cap

365.5M

52 Wk Range

$9.10 - $35.80

Previous Close

$17.59

Open

$17.84

Volume

228,693

Day Range

$17.65 - $18.57

Enterprise Value

307.3M

Cash

58.22M

Avg Qtr Burn

-18.81M

Insider Ownership

2.15%

Institutional Own.

74.84%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
FB102 Details Celiac Disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FB102 (Anti-CD122 Antibody) Details Alopecia Areata	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FB102 (Anti-CD122 Antibody) Details Vitiligo	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FB102 Details Graft-versus-host disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.